Current Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source. 




Doris Duke Physician Scientist Fellowship  


The Doris Duke Charitable Foundation (DDCF) has announced the creation of the Doris Duke Physician Scientist Fellowship, an inaugural program which will open for application in April 2019 to clinical investigators currently engaged in subspecialty training. Through the Physician Scientist Fellowship, DDCF will aim to encourage emerging physician scientists to pursue careers in clinical research and hopes to promote their transition into faculty-level positions. 

Applications will open in April 2019.

Learn more about this fellowship>>  


Request for Information to Better Facilitate Cancer Systems Epidemiology Research

The NCI seeks broad input from members of the scientific community to identify areas of need and opportunities for interdisciplinary, systems science research focused on cancer risk and prognosis, particularly data analysis and interpretation when applying comprehensive analytical approaches, such as systems or computational modeling, to study of the etiology of cancer.  

Response Date: April 30, 2019



Administrative Supplement for Research on Bioethical Issues (PA-19-217)

The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support research on bioethical issues to develop an evidence base that may inform future policy directions. Applicants may propose to supplement parent awards focused on bioethics or to add a component related to bioethics to a parent award in which bioethics was not the focus.

Areas of high priority research include, but are not limited to, the bioethical, legal, and societal implications of the following: New and emerging technology development and use; clinical and non-clinical data sharing; precision and personalized medicine; research privacy and security; learning healthcare systems; crowdsourcing; participant-driven research and consumer generated data; patient/participant representation in research oversight; special and vulnerable population research, and more. 

Application Deadline: May 13, 2019, by 5:00 PM local time of applicant organization. 

For additional information about PA-19-217>>


Department of Defense Lung Cancer Research Program

Idea Development Award
 
Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent); or
New Investigators: Investigators must meet the following criteria at the application submission deadline date:
• Have not previously received a LCRP Idea Development Award or LCRP Early Investigator Synergistic Idea Award
• Be within 10 years of first faculty appointment (or equivalent)
• Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
• Emphasis on innovation and impact.
• New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.
• Clinical trials not allowed.
• Preliminary data required, but may be from outside of lung cancer.
• Relevance Military Health strongly encouraged.

• Maximum funding of $350,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Preproposal Deadline: May 15, 2019


Investigator-Initiated Translational Research Award 
• Independent investigators at or above the level of Assistant Professor (or equivalent)
• Supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations.
• Intended to fund a broad range of translational studies.
• Clinical trials not allowed.
• Preliminary data required.
• Relevance to Military Health strongly encouraged.

• Maximum funding of $400,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Preproposal Deadline: May 15, 2019


Translational Research Partnership Award 
• Investigators at or above the level of Assistant Professor (or equivalent)
• Supports partnerships between clinicians and research scientists that accelerate ideas in lung cancer into clinical applications.
• One partner is strongly encouraged to be from Department of Defense military treatment facility or laboratory, or Veterans Affairs medical center.
• Clinical trials are allowed.
• Nontraditional Partnerships are encouraged.
• Preliminary data required.
• Relevance to Military Health strongly encouraged.

• Maximum combined funding of $900,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.


Preproposal Deadline: May 15, 2019



Notice of Special Interest: Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models

Through funds available from the Cancer Moonshot InitiativeSM, and pursuant to the NIH interest in advancing human tissue models that do not rely on human fetal tissue (NOT-OD-19-042), the National Cancer Institute (NCI) is inviting applications for administrative supplements to improve representation of the human immune system in ongoing cancer modeling development projects that can be utilized in immuno-oncology research. Progress for cancer research is highly dependent on the model systems employed. While substantial progress has been made to establish models of increasing complexity to recapitulate aspects of human disease, a critical shortcoming persists for representation of the human immune system in those models. For example, various models can recapitulate key aspects of human T cell immunity but are less able to recapitulate human innate immunity and antibody responses, regardless of the human tissue source. In addition, few direct comparisons have been conducted of mice with humanized immune systems (HIS) derived using fetal vs. non-fetal human tissue sources (https://www.niaid.nih.gov/research/humanized-mouse-model-workshop). HIS mice are used extensively in immuno-oncology research, which is a high priority field of research with support through the Cancer Moonshot Initiative. 

Application Deadline: June 3, 2019

Learn More>>



Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional) (PA-19-200)

NCI is a participating organization.

The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.

Application Deadline: June 5, 2019. 

Learn More>>



Biology of Bladder Cancer (R01/R21)

This FOA encourages applications investigating the biology and underlying mechanisms of bladder cancer.

Application Deadlines: (R01): June 5, 2019 (R21): June 16, 2019




Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed) (PAR-19-198)

The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.

Application Deadline: June 10, 2019

Learn More>>



Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed) (PAR-19-199)


The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation. 

Application Deadline: June 10, 2019

Learn More>>


ITCR: innovative algorithms (R21 Clinical Trial Optional) (RFA-CA-19-038)

The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge.

Application Deadline: June 11, 2019, by 5:00 PM local time of applicant organization.

Learn More>>


Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) (RFA-CA-19-039)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications.

Application Deadline: June 11, 2019, by 5:00 PM local time of applicant organization. 

Learn More>>


Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) (RFA-CA-19-040)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field.

Application Deadline: June 11, 2019, by 5:00 PM local time of applicant organization. 

Learn More>>



Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) (RFA-CA-19-041)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources.

Application Deadline: June 11, 2019, by 5:00 PM local time of applicant organization. 

Learn More>>


Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional) (PA-19-201)

NCI is a participating organization.

The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.

Application Deadline: June 16, 2019

Learn More>>


Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required) (RFA-CA-19-035)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This FOA solicits applications that develop and test models of care for adult survivors of cancer who are transitioning from active treatment to follow-up care. Through this FOA, the NCI intends to support multi-level interventions that enhance communication, collaboration, and coordination among oncology and non-oncology providers to improve cancer survivor outcomes.

Application Deadline: June 28, 2019, by 5:00 PM local time of applicant organization. 

Learn More>>



Tobacco Regulatory Science (R01 Clinical Trial Optional)


The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health.

Estimated Application Due Date: July 19, 2019




Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)

The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or AIDS.

Application Deadline: August 1, 2019


The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process. 

The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants. 

Current opportunities are listed below. 

View a full list of grant opportunities available throughout the year>> 



Career Enhancement Program (CEP) of the Yale SPORE in Lung Cancer

The Career Enhancement Program (CEP) of the Yale SPORE in Lung Cancer has been established to educate the next generation of investigators committed to translational research in lung cancer. The CEP will provide support of up to $50,000 to promising junior investigators and/or establish investigators who have not previously conducted lung cancer focused research. Proposed pilot projects should be innovative and be focused on a broad spectrum of research, and/or technology development applicable to human lung cancer risk, prevention, diagnosis, prognosis, or treatment. Award amounts of up to $50,000 for one year will commence August 1, 2019.

Letters of Intent Deadline: 5:00 PM, April 25, 2019 
https://www.yalecancercenter.org/lungspore/funding/career/


Developmental Research Program of the Yale SPORE in Lung Cancer

The Yale SPORE in Lung Cancer’s Developmental Research Program provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full Yale SPORE in Lung Cancer project. The purpose is also to generate preliminary data or evidence of collaboration for new NCI grant applications. Projects of more limited scope (e.g., for smaller amounts and/or for shorter periods of time) will be at no competitive disadvantage in the review process. Projects with multi-disciplinary collaborations and promising translational research potential will get favorable scores in review. Award amounts of up to $50,000 for one year will commence August 1, 2019.

Letters of Intent Deadline: 5:00 PM, April 25, 2019 
https://www.yalecancercenter.org/lungspore/funding/developmental/


2019 Phi Beta Psi Sorority Cancer Research Grant


Phi Beta Psi Sorority is a national, civic, non-profit organization whose National Project is to advance cancer research nationwide to improve prevention, diagnosis and treatment by providing research grants to qualified investigators addressing original questions and hypotheses to be explored in basic and clinical studies in the field of cancer. Research application must be focused on brain, breast, colorectal, endometrial, lung, ovarian, pancreatic or prostate cancer.

Preference is given to Young Investigators with documented evidence of potential for conducting novel research of either basic or clinical aspects of cancer and cancer-related problems. Applications from Established Investigators exploring new and innovative areas of cancer research also will be considered.

Internal Competition Procedure:

1. A brief description of your proposed research project (two-page maximum). Applications should be 11-pt Arial, Helvetica, or TNR font; margins no less than 0.5 inch all around. Literature citations do not count against this page limit.
2. NIH Biographical sketch for PI(s)

Application Deadline: Wednesday, May 1, 2019

To apply, please click here


Luminary Award of Excellence

The YNHH Smilow Luminary Award of Excellence will serve to recognize, and ceremoniously acknowledge, those individuals and/or teams who consistently exceed performance expectations and deliver high quality cancer care for our patients, families and the health system through community service, optimization/ innovative solutions, patient experience, leadership and research initiatives. Nominations should be submitted directly to  Luminary@ynhh.org